Incyte Corporation (NASDAQ: INCY) Stock Competitors & Peer Comparison

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, VRTX has a market cap of 128.1B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while VRTX trades at $504.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas VRTX's P/E ratio is 26.52. In terms of profitability, INCY's ROE is +0.30%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, INCY is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for INCY.Check VRTX's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, REGN has a market cap of 75.7B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while REGN trades at $735.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas REGN's P/E ratio is 16.11. In terms of profitability, INCY's ROE is +0.30%, compared to REGN's ROE of +0.14%. Regarding short-term risk, INCY is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for INCY.Check REGN's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, MRNA has a market cap of 75.4B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while MRNA trades at $190.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas MRNA's P/E ratio is -23.31. In terms of profitability, INCY's ROE is +0.30%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, INCY is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for INCY.Check MRNA's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas VRNA's P/E ratio is -102.80. In terms of profitability, INCY's ROE is +0.30%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, INCY is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for INCY.Check VRNA's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, ARGX has a market cap of 57.2B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while ARGX trades at $919.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas ARGX's P/E ratio is 33.14. In terms of profitability, INCY's ROE is +0.30%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, INCY is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for INCY.Check ARGX's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, RVMDW has a market cap of 45.2B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while RVMDW trades at $11.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas RVMDW's P/E ratio is -1.31. In terms of profitability, INCY's ROE is +0.30%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, INCY is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for INCY.Check RVMDW's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, RVMD has a market cap of 43.9B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while RVMD trades at $206.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas RVMD's P/E ratio is -23.43. In terms of profitability, INCY's ROE is +0.30%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, INCY is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for INCY.Check RVMD's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas SGEN's P/E ratio is -57.19. In terms of profitability, INCY's ROE is +0.30%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, INCY is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for INCY.Check SGEN's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, ONC has a market cap of 38.3B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while ONC trades at $358.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas ONC's P/E ratio is 63.04. In terms of profitability, INCY's ROE is +0.30%, compared to ONC's ROE of +0.14%. Regarding short-term risk, INCY is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for INCY.Check ONC's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, ALNY has a market cap of 29.4B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while ALNY trades at $219.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas ALNY's P/E ratio is 39.59. In terms of profitability, INCY's ROE is +0.30%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, INCY is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for INCY.Check ALNY's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, ROIV has a market cap of 25.8B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while ROIV trades at $35.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas ROIV's P/E ratio is -33.98. In terms of profitability, INCY's ROE is +0.30%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, INCY is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for INCY.Check ROIV's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, BNTX has a market cap of 24.3B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while BNTX trades at $96.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas BNTX's P/E ratio is -12.57. In terms of profitability, INCY's ROE is +0.30%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, INCY is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for INCY.Check BNTX's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, INSM has a market cap of 24.1B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while INSM trades at $111.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas INSM's P/E ratio is -27.04. In terms of profitability, INCY's ROE is +0.30%, compared to INSM's ROE of -1.11%. Regarding short-term risk, INCY is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for INCY.Check INSM's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, UTHR has a market cap of 23B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while UTHR trades at $541.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas UTHR's P/E ratio is 19.38. In terms of profitability, INCY's ROE is +0.30%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, INCY is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for INCY.Check UTHR's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, GMAB has a market cap of 21.3B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while GMAB trades at $34.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas GMAB's P/E ratio is 26.19. In terms of profitability, INCY's ROE is +0.30%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, INCY is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for INCY.Check GMAB's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas BGNE's P/E ratio is -22.55. In terms of profitability, INCY's ROE is +0.30%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, INCY is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for INCY.Check BGNE's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, INCY's ROE is +0.30%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, INCY is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for INCY.Check DNA-WT's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, JAZZ has a market cap of 14.8B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while JAZZ trades at $235.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas JAZZ's P/E ratio is 8.79. In terms of profitability, INCY's ROE is +0.30%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, INCY is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for INCY.Check JAZZ's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, EXEL has a market cap of 14.7B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while EXEL trades at $58.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas EXEL's P/E ratio is 16.68. In terms of profitability, INCY's ROE is +0.30%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, INCY is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for INCY.Check EXEL's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, NBIX has a market cap of 14.4B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while NBIX trades at $143.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas NBIX's P/E ratio is 20.69. In terms of profitability, INCY's ROE is +0.30%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, INCY is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for INCY.Check NBIX's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, ASND has a market cap of 14.2B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while ASND trades at $227.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas ASND's P/E ratio is -94.16. In terms of profitability, INCY's ROE is +0.30%, compared to ASND's ROE of +1.90%. Regarding short-term risk, INCY is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for INCY.Check ASND's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, SMMT has a market cap of 13.4B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while SMMT trades at $16.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas SMMT's P/E ratio is -14.96. In terms of profitability, INCY's ROE is +0.30%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, INCY is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for INCY.Check SMMT's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, BBIO has a market cap of 13.2B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while BBIO trades at $67.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas BBIO's P/E ratio is -17.98. In terms of profitability, INCY's ROE is +0.30%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, INCY is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for INCY.Check BBIO's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, HALO has a market cap of 12.7B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while HALO trades at $109.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas HALO's P/E ratio is 19.95. In terms of profitability, INCY's ROE is +0.30%, compared to HALO's ROE of +1.81%. Regarding short-term risk, INCY is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for INCY.Check HALO's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas KRTX's P/E ratio is -28.09. In terms of profitability, INCY's ROE is +0.30%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, INCY is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for INCY.Check KRTX's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, TXG has a market cap of 11.9B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while TXG trades at $93.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas TXG's P/E ratio is -158.47. In terms of profitability, INCY's ROE is +0.30%, compared to TXG's ROE of -0.09%. Regarding short-term risk, INCY is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for INCY.Check TXG's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, TWST has a market cap of 11.7B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while TWST trades at $188.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas TWST's P/E ratio is -84.99. In terms of profitability, INCY's ROE is +0.30%, compared to TWST's ROE of -0.30%. Regarding short-term risk, INCY is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for INCY.Check TWST's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, MDGL has a market cap of 11.5B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while MDGL trades at $499.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas MDGL's P/E ratio is -39.02. In terms of profitability, INCY's ROE is +0.30%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, INCY is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for INCY.Check MDGL's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while TECH trades at $72.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas TECH's P/E ratio is 37.32. In terms of profitability, INCY's ROE is +0.30%, compared to TECH's ROE of +0.09%. Regarding short-term risk, INCY is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for INCY.Check TECH's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas RNAM's P/E ratio is -17.39. In terms of profitability, INCY's ROE is +0.30%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, INCY is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for INCY.Check RNAM's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while BMRN trades at $57.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas BMRN's P/E ratio is 27.49. In terms of profitability, INCY's ROE is +0.30%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, INCY is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for INCY.Check BMRN's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, IBRX has a market cap of 10.8B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while IBRX trades at $10.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas IBRX's P/E ratio is -10.60. In terms of profitability, INCY's ROE is +0.30%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, INCY is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for INCY.Check IBRX's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas RXDX's P/E ratio is -56.47. In terms of profitability, INCY's ROE is +0.30%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, INCY is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for INCY.Check RXDX's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, KRYS has a market cap of 9.5B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while KRYS trades at $322.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas KRYS's P/E ratio is 40.39. In terms of profitability, INCY's ROE is +0.30%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, INCY is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for INCY.Check KRYS's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, AXSM has a market cap of 9.2B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while AXSM trades at $179.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas AXSM's P/E ratio is -46.80. In terms of profitability, INCY's ROE is +0.30%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, INCY is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for INCY.Check AXSM's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas NUVL's P/E ratio is -21.79. In terms of profitability, INCY's ROE is +0.30%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, INCY is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for INCY.Check NUVL's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, ARWR has a market cap of 9B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while ARWR trades at $64.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas ARWR's P/E ratio is -28.53. In terms of profitability, INCY's ROE is +0.30%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, INCY is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for INCY.Check ARWR's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, PTGX has a market cap of 9B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while PTGX trades at $140.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas PTGX's P/E ratio is 135.98. In terms of profitability, INCY's ROE is +0.30%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, INCY is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for INCY.Check PTGX's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while CRNX trades at $84.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas CRNX's P/E ratio is -16.86. In terms of profitability, INCY's ROE is +0.30%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, INCY is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for INCY.Check CRNX's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, KYMR has a market cap of 8.8B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while KYMR trades at $107.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas KYMR's P/E ratio is -33.56. In terms of profitability, INCY's ROE is +0.30%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, INCY is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for INCY.Check KYMR's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas IMGN's P/E ratio is -111.55. In terms of profitability, INCY's ROE is +0.30%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, INCY is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for INCY.Check IMGN's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas BPMC's P/E ratio is -51.58. In terms of profitability, INCY's ROE is +0.30%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, INCY is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for INCY.Check BPMC's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while APGE trades at $135.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas APGE's P/E ratio is -31.19. In terms of profitability, INCY's ROE is +0.30%, compared to APGE's ROE of -0.30%. Regarding short-term risk, INCY is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for INCY.Check APGE's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while TGTX trades at $54.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas TGTX's P/E ratio is 19.67. In terms of profitability, INCY's ROE is +0.30%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, INCY is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for INCY.Check TGTX's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, PRAX has a market cap of 8.2B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while PRAX trades at $295.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas PRAX's P/E ratio is -22.85. In terms of profitability, INCY's ROE is +0.30%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, INCY is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for INCY.Check PRAX's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas CERE's P/E ratio is -16.47. In terms of profitability, INCY's ROE is +0.30%, compared to CERE's ROE of -0.72%. Regarding short-term risk, INCY is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for INCY.Check CERE's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, CYTK has a market cap of 8.2B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while CYTK trades at $65.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas CYTK's P/E ratio is -9.09. In terms of profitability, INCY's ROE is +0.30%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, INCY is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for INCY.Check CYTK's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, PCVX has a market cap of 8.2B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while PCVX trades at $56.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas PCVX's P/E ratio is -7.40. In terms of profitability, INCY's ROE is +0.30%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, INCY is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for INCY.Check PCVX's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, SYRE has a market cap of 8.1B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while SYRE trades at $93.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas SYRE's P/E ratio is -47.79. In terms of profitability, INCY's ROE is +0.30%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, INCY is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for INCY.Check SYRE's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, CAI has a market cap of 8B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while CAI trades at $28.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas CAI's P/E ratio is 79.52. In terms of profitability, INCY's ROE is +0.30%, compared to CAI's ROE of +0.19%. Regarding short-term risk, INCY is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for INCY.Check CAI's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas MTSR's P/E ratio is -23.58. In terms of profitability, INCY's ROE is +0.30%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, INCY is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for INCY.Check MTSR's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, IONS has a market cap of 7.2B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while IONS trades at $43.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas IONS's P/E ratio is -13.31. In terms of profitability, INCY's ROE is +0.30%, compared to IONS's ROE of -1.11%. Regarding short-term risk, INCY is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for INCY.Check IONS's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, IMVT has a market cap of 6.9B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while IMVT trades at $33.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas IMVT's P/E ratio is -11.92. In terms of profitability, INCY's ROE is +0.30%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, INCY is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for INCY.Check IMVT's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas MRUS's P/E ratio is -17.05. In terms of profitability, INCY's ROE is +0.30%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, INCY is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for INCY.Check MRUS's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, ABVX has a market cap of 6.8B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while ABVX trades at $92.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas ABVX's P/E ratio is -15.22. In terms of profitability, INCY's ROE is +0.30%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, INCY is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for INCY.Check ABVX's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas ACLX's P/E ratio is -28.27. In terms of profitability, INCY's ROE is +0.30%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, INCY is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for INCY.Check ACLX's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas RETA's P/E ratio is -66.29. In terms of profitability, INCY's ROE is +0.30%, compared to RETA's ROE of +0.47%. Regarding short-term risk, INCY is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for INCY.Check RETA's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while BLTE trades at $159.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas BLTE's P/E ratio is -85.33. In terms of profitability, INCY's ROE is +0.30%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, INCY is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for INCY.Check BLTE's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, RYTM has a market cap of 6.4B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while RYTM trades at $92.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas RYTM's P/E ratio is -29.85. In terms of profitability, INCY's ROE is +0.30%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, INCY is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for INCY.Check RYTM's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, IOVA has a market cap of 6.3B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while IOVA trades at $14.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas IOVA's P/E ratio is -19.47. In terms of profitability, INCY's ROE is +0.30%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, INCY is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for INCY.Check IOVA's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas CNTA's P/E ratio is -22.63. In terms of profitability, INCY's ROE is +0.30%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, INCY is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for INCY.Check CNTA's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, LGND has a market cap of 6.1B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while LGND trades at $302.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas LGND's P/E ratio is 33.26. In terms of profitability, INCY's ROE is +0.30%, compared to LGND's ROE of +0.20%. Regarding short-term risk, INCY is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for INCY.Check LGND's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, CGON has a market cap of 5.9B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while CGON trades at $67.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas CGON's P/E ratio is -25.05. In terms of profitability, INCY's ROE is +0.30%, compared to CGON's ROE of -0.25%. Regarding short-term risk, INCY is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for INCY.Check CGON's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, KOD has a market cap of 5.9B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while KOD trades at $94.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas KOD's P/E ratio is -22.65. In terms of profitability, INCY's ROE is +0.30%, compared to KOD's ROE of -2.73%. Regarding short-term risk, INCY is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for INCY.Check KOD's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas CDTX's P/E ratio is -19.77. In terms of profitability, INCY's ROE is +0.30%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, INCY is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for INCY.Check CDTX's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, SRRK has a market cap of 5.6B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while SRRK trades at $46.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas SRRK's P/E ratio is -13.57. In terms of profitability, INCY's ROE is +0.30%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, INCY is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for INCY.Check SRRK's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, INCY's ROE is +0.30%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, INCY is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for INCY.Check ABCM's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas ISEE's P/E ratio is -22.44. In terms of profitability, INCY's ROE is +0.30%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, INCY is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for INCY.Check ISEE's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, CRSP has a market cap of 5.3B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while CRSP trades at $55.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas CRSP's P/E ratio is -11.64. In terms of profitability, INCY's ROE is +0.30%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, INCY is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for INCY.Check CRSP's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, COGT has a market cap of 5.3B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while COGT trades at $31.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas COGT's P/E ratio is -14.70. In terms of profitability, INCY's ROE is +0.30%, compared to COGT's ROE of -0.73%. Regarding short-term risk, INCY is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for INCY.Check COGT's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, PTCT has a market cap of 5.3B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while PTCT trades at $63.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas PTCT's P/E ratio is -27.24. In terms of profitability, INCY's ROE is +0.30%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, INCY is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for INCY.Check PTCT's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while TVTX trades at $56.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas TVTX's P/E ratio is -126.51. In terms of profitability, INCY's ROE is +0.30%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, INCY is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for INCY.Check TVTX's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas APLS's P/E ratio is 38.35. In terms of profitability, INCY's ROE is +0.30%, compared to APLS's ROE of +0.40%. Regarding short-term risk, INCY is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for INCY.Check APLS's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, ERAS has a market cap of 5.1B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while ERAS trades at $14.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas ERAS's P/E ratio is -15.85. In terms of profitability, INCY's ROE is +0.30%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, INCY is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for INCY.Check ERAS's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, ORKA has a market cap of 5.1B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while ORKA trades at $84.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas ORKA's P/E ratio is -43.57. In terms of profitability, INCY's ROE is +0.30%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, INCY is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for INCY.Check ORKA's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, MIRM has a market cap of 5.1B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while MIRM trades at $82.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas MIRM's P/E ratio is -5.70. In terms of profitability, INCY's ROE is +0.30%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, INCY is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for INCY.Check MIRM's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, DFTX has a market cap of 5B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while DFTX trades at $37.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas DFTX's P/E ratio is N/A. In terms of profitability, INCY's ROE is +0.30%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, INCY is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for INCY.Check DFTX's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, DNTH has a market cap of 4.9B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while DNTH trades at $88.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas DNTH's P/E ratio is -21.26. In terms of profitability, INCY's ROE is +0.30%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, INCY is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for INCY.Check DNTH's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, MANE has a market cap of 4.9B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while MANE trades at $116.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas MANE's P/E ratio is -37.17. In terms of profitability, INCY's ROE is +0.30%, compared to MANE's ROE of -0.38%. Regarding short-term risk, INCY is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for INCY.Check MANE's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas TERN's P/E ratio is -51.41. In terms of profitability, INCY's ROE is +0.30%, compared to TERN's ROE of -0.20%. Regarding short-term risk, INCY is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for INCY.Check TERN's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas FOLD's P/E ratio is -161.00. In terms of profitability, INCY's ROE is +0.30%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, INCY is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for INCY.Check FOLD's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, ADPT has a market cap of 4.5B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while ADPT trades at $28.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas ADPT's P/E ratio is -69.15. In terms of profitability, INCY's ROE is +0.30%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, INCY is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for INCY.Check ADPT's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas AKRO's P/E ratio is -14.57. In terms of profitability, INCY's ROE is +0.30%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, INCY is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for INCY.Check AKRO's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas ALPN's P/E ratio is -101.52. In terms of profitability, INCY's ROE is +0.30%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, INCY is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for INCY.Check ALPN's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, EWTX has a market cap of 4.5B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while EWTX trades at $41.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas EWTX's P/E ratio is -22.38. In terms of profitability, INCY's ROE is +0.30%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, INCY is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for INCY.Check EWTX's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas OPT's P/E ratio is -1.52. In terms of profitability, INCY's ROE is +0.30%, compared to OPT's ROE of +1.18%. Regarding short-term risk, INCY is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for INCY.Check OPT's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas PRTC's P/E ratio is -3.78. In terms of profitability, INCY's ROE is +0.30%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, INCY is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for INCY.Check PRTC's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, ABCL has a market cap of 4.2B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while ABCL trades at $13.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas ABCL's P/E ratio is -25.44. In terms of profitability, INCY's ROE is +0.30%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, INCY is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for INCY.Check ABCL's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, RLAY has a market cap of 4.2B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while RLAY trades at $18.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas RLAY's P/E ratio is -12.08. In terms of profitability, INCY's ROE is +0.30%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, INCY is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for INCY.Check RLAY's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas MRTX's P/E ratio is -4.82. In terms of profitability, INCY's ROE is +0.30%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, INCY is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for INCY.Check MRTX's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas CPRX's P/E ratio is 17.49. In terms of profitability, INCY's ROE is +0.30%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, INCY is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for INCY.Check CPRX's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, TNGX has a market cap of 3.8B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while TNGX trades at $23.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas TNGX's P/E ratio is -28.00. In terms of profitability, INCY's ROE is +0.30%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, INCY is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for INCY.Check TNGX's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas RYZB's P/E ratio is -57.86. In terms of profitability, INCY's ROE is +0.30%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, INCY is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for INCY.Check RYZB's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas CBAY's P/E ratio is -32.81. In terms of profitability, INCY's ROE is +0.30%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, INCY is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for INCY.Check CBAY's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, XENE has a market cap of 3.7B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while XENE trades at $38.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas XENE's P/E ratio is -8.09. In terms of profitability, INCY's ROE is +0.30%, compared to XENE's ROE of -0.44%. Regarding short-term risk, INCY is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for INCY.Check XENE's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, TLX has a market cap of 3.6B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while TLX trades at $10.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas TLX's P/E ratio is 110.13. In terms of profitability, INCY's ROE is +0.30%, compared to TLX's ROE of +0.07%. Regarding short-term risk, INCY is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for INCY.Check TLX's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, IDYA has a market cap of 3.6B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while IDYA trades at $37.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas IDYA's P/E ratio is -19.26. In terms of profitability, INCY's ROE is +0.30%, compared to IDYA's ROE of -0.16%. Regarding short-term risk, INCY is less volatile compared to IDYA. This indicates lower risk in terms of short-term price fluctuations for INCY.Check IDYA's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas SWTX's P/E ratio is -13.78. In terms of profitability, INCY's ROE is +0.30%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, INCY is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for INCY.Check SWTX's competition here

Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INCY stands at 23.4B. In comparison, PBLS has a market cap of 3.5B. Regarding current trading prices, INCY is priced at $115.30 on the NASDAQ, while PBLS trades at $30.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INCY currently has a P/E ratio of 15.50, whereas PBLS's P/E ratio is -16.11. In terms of profitability, INCY's ROE is +0.30%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, INCY is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for INCY.Check PBLS's competition here